ASCO GI 2022

Complete Coverage

Adagrasib Shows Promising Activity in Gastrointestinal Cancers

In the KRYSTAL-1 trial, adagrasib produced a 100% disease control rate in patients with gastrointestinal cancers.

COVID-19 Vaccination During Chemotherapy Deemed Safe for Gastrointestinal Cancers

The study revealed no new safety signals compared with previous reports.

The Role of Twitter in Colorectal Cancer Awareness

The most common topics of tweets were early detection of disease, bereavement, and research.

Oxaliplatin Does Not Benefit Older Patients With Metastatic Colorectal Cancer

Oxaliplatin did not prolong progression-free survival and was associated with more adverse events.

Stopping Adjuvant Treatment Early May Decrease DFS, OS in Stage III Colon Cancer

Early treatment discontinuation was associated with a decrease in survival, but early oxaliplatin discontinuation was not.

First Positive First-Line Immuno-Chemotherapy Results for Biliary Tract Cancer

Adding durvalumab to gemcitabine and cisplatin improved progression-free and overall survival.

Eryaspase Does Not Improve PFS or OS in Advanced Pancreatic Cancer

The median overall survival was 7.5 months in the eryaspase arm and 6.7 months in the chemotherapy-alone arm.

STRIDE Regimen Extends Survival in Unresectable Hepatocellular Carcinoma

The median overall survival was 16.4 months with STRIDE and 13.8 months with sorafenib.

TACE Improves Efficacy of Lenvatinib in Advanced Hepatocellular Carcinoma

TACE improved responses and survival outcomes.

COVID-19 Pandemic Did Not Affect Care of Pancreatic Cancer Patients

Patients with pancreatic ductal adenocarcinoma may have been spared the COVID-related delays in care seen for other cancers, according to researchers.

Sintilimab Improves Response to Chemotherapy in Advanced Pancreatic Cancer

The improvement in response did not translate to a survival benefit.

Neoadjuvant DCF Dubbed New Standard Care for Locally Advanced Esophageal Cancer

Adding docetaxel to cisplatin and fluorouracil improved overall survival.

Outcomes Similar With Etoposide or Irinotecan Plus Cisplatin in Gastrointestinal Neuroendocrine Carcinoma

Both platinum-based chemotherapy regimens are standard of care for digestive system neuroendocrine carcinoma.

Adjuvant S-1 Improves OS, Is Labelled New Standard in Biliary Tract Cancer

Adjuvant S-1 improved survival over surgery alone.

Could Immunotherapy Delay, Eliminate Surgery in Gastric/GEJ Cancer?

About 59% of patients achieved a pathologic complete response.

Gut Microbiome, SNPs May Help Predict Nivolumab-Induced Toxicity

Host-related biomarkers might predict toxicities associated with nivolumab treatment in patients with advanced gastric cancer

Trastuzumab Deruxtecan Improved OS, ORR in HER2+ Gastric/GEJ Adenocarcinoma

The updated results are from a median survival follow-up of 18.5 months and 133 overall survival events.

No Benefit With Pembrolizumab Plus Chemo in PD-L1+ Gastric/GEJ Cancer

The addition of pembrolizumab to chemotherapy did not improve progression-free or overall survival.